Reitsamer R, Peintinger F, Sedlmayer F, Kopp M, Menzel C, Cimpoca W, Glueck S, Rahim H, Kopp P, Deutschmann H, Merz F, Brandis M, Kogelnik H
Landesklinik für Spezielle Gynäkologie, Landeskliniken Salzburg, Müllner Hauptstrasse 48, 5020, Salzburg, Austria.
Eur J Cancer. 2002 Aug;38(12):1607-10. doi: 10.1016/s0959-8049(02)00116-8.
Conventional radiotherapy after breast-conserving therapy is confined to 50-55 Gy external beam radiation therapy (EBRT) to the whole breast and 10-16 Gy external boost radiation to the tumour bed or brachytherapy to the tumour bed. Local recurrence rate after breast-conserving surgery varies between 5 and 18%. External boost radiation can partially miss the tumour bed and therefore can result in local failure. Intra-operative radiotherapy (IORT) as a high precision boost can prevent a 'geographical miss'. From October 1998 to December 2000, 156 patients with stage I and stage II breast cancer were operated upon in a dedicated IORT facility. After local excision of the tumour, the tumour bed was temporarily approximated by sutures to bring the tissue in the radiation planning target volume. A single dose of 9 Gy was applied to the 90% reference isodose with energies ranging from 4 to 15 MeV, using round applicator tubes 4-8 cm in diameter. After wound healing, the patients received additional 51-56 Gy EBRT to the whole breast. No acute complications associated with IORT were observed. In 5 patients, a secondary mastectomy had to be performed because of tumour multicentricity in the final pathological report or excessive intraductal component. 2 patients developed rib necroses. In 7 patients, wound healing problems occurred. After a mean follow-up of 18 months, no local recurrences were observed. Cosmesis of the breast was very good and comparable to patients without IORT. Preliminary data suggest that IORT given as a boost after breast-conserving surgery could be a reliable alternative to conventional postoperative fractionated boost radiation by accurate dose delivery and avoiding geographical misses, by enabling smaller treatment volumes and complete skin-sparing and by reducing postoperative radiation time by 7-14 days.
保乳治疗后的传统放疗包括对全乳进行50 - 55 Gy的外照射放疗(EBRT),以及对瘤床进行10 - 16 Gy的外照射追加放疗或对瘤床进行近距离放疗。保乳手术后的局部复发率在5%至18%之间。外照射追加放疗可能会部分遗漏瘤床,从而导致局部治疗失败。术中放疗(IORT)作为一种高精度的追加放疗可避免“区域遗漏”。1998年10月至2000年12月,156例I期和II期乳腺癌患者在专门的IORT设施中接受了手术。在肿瘤局部切除后,用缝线暂时缝合瘤床,使组织进入放射治疗计划靶体积。使用直径4 - 8 cm的圆形施源器管,以4至15 MeV的能量对90%参考等剂量线给予9 Gy的单次剂量照射。伤口愈合后,患者接受全乳额外的51 - 56 Gy EBRT。未观察到与IORT相关的急性并发症。5例患者因最终病理报告显示肿瘤多中心性或导管内成分过多而不得不进行二次乳房切除术。2例患者出现肋骨坏死。7例患者出现伤口愈合问题。平均随访18个月后,未观察到局部复发。乳房的美容效果非常好,与未接受IORT的患者相当。初步数据表明,保乳手术后给予IORT作为追加放疗,通过精确的剂量给予、避免区域遗漏、实现更小的治疗体积和完全保留皮肤以及将术后放疗时间缩短7 - 14天,可能是传统术后分次追加放疗的可靠替代方法。